Study ID: Tracer
Indication: Admitted to hospital with heart attack
Physician conducting the study: Robert Merritt, M.D.
Study Status: Enrolling new patients

The purpose of this research study is to evaluate the clinical benefit of the study drug and how it may reduce the complications related to coronary events when given to patients with a history of chest pain.

For more information about this study, please contact Kristi Miller, RN at (417) 820-4338.
 

Study ID: Virgo study
Physician conducting the study:  Lakshmi Parvathaneni, M.D.

This is a study of men and women who are 55 years of age or younger, who have had heart attacks.   The study is designed to help researchers and doctors better understand the recovery period by examining certain things that can influence recovery from a heart attack.  Some of these things include heart attack symptoms, daily functioning and important relationships in your life.  By collecting this information researchers can try to understand how these things affect recovery from a heart attack and if they influence recovery differently for men and women.

For more information about this study, please contact Rebecca Baker, RN at (417)820-6184.
 

Study ID:  Xience
Indication:  Any patient going for an angiogram of their coronary arteries or heart arteries who may have an intervention or balloon / stent procedure for a possible blockage.
Physician conducting the study:  Robert Merritt, M.D.

The purpose of this study is to evaluate patients who receive a Xience stent in one or more of their heart arteries.  The study evaluates blood thinner treatment, future heart problems, and the quality of life of patients who have these stents by questionnaires.

For more information about this study, please contact Rebecca Baker, RN at (417)820-6184.
 

Study ID: Ascend HF
Indication: Admitted to hospital with worsening heart failure
Physician conducting the study: Donald Myears, M.D.
Study Status: Enrolling new patients

The purpose of this study is to evaluate if the drug that is being researched, nesiritide as compared to placebo (an inactive substance which looks like the real drug), plus the usual treatment for acute decompensated heart failure (standard of care) helps: improve breathing difficulties, reduces rehospitalization, and prolongs patients lives.

For more information please contact Kristi Miller, RN at (417) 820-4338.
 

Study ID: CHOICE
Indication: Carotid Artery Stenosis
Physician conducting the study: Robert Merritt, M.D.
Study Status: Enrolling New patients

This study includes individuals who have a significant narrowing in the carotid artery (the artery in the neck that supplies blood to the brain).  This narrowing can cause strokes or short-lived blindness, and is often treated by implanting a stent that widens the narrowed portion of the artery.  The purpose of this study is to collect more information on the safety and effectiveness of the new stent system being used.  The study is a post market study sponsored by ABBOTT. Only patients considered high-risk for carotid endarterectomy and meeting the FDA approved/cleared indications for use of the device will be included in the study.  The physician has the option to use either the Acculink system or the Xact system for the stent and embolic protection.

For more information please contact Kristi Miller, RN at (417) 820-4338.
 

Study ID: Sapphire
Physician conducting the study: Robert Merritt, M.D.
Study Status: Enrolling New patients

This study includes individuals who have a significant narrowing in the carotid artery (the artery in the neck that supplies blood to the brain).  This narrowing can cause strokes or short-lived blindness, and is often treated by implanting a stent that widens the narrowed portion of the artery.  The purpose of this study is to collect more information on the safety and effectiveness of the new stent system being used.

The study is a post market study sponsored by Cordis. Only patients considered high-risk for carotid endarterectomy and meeting the FDA approved/cleared indications for use of the device will be included in the study.  The physician will use the Precise carotid stent system and the Angioguard embolic protection.

For more information please contact Rebecca Baker, RN at (417) 820-6184.
 

Study ID: ROCKET-AF
Indication: Atrial Fibrillation
Physician conducting the study: Donald Myears, M.D.
Study Status: Enrolling new patients

The study drug, Rivaroxaban is being compared to warfarin in high risk subjects with an irregular heart beat or atrial fibrillation.  This medication is a blood thinner designed to reduce the risk of blood clot formation that can lead to stroke.  The study will evaluate the effectiveness of the drug in preventing strokes or any other blood clotting event.

For more information about this study, please contact Sherri Swafford, RN at (417) 820-9587
 

Study ID:  Magellan Study
Physician Conducting Study:  Shang-Chuin Lee, MD
Study Status:  Enrolling new patients

This study is for patients with paroxysmal atrial fibrillation or intermittent irregular heart beat of the upper chambers of the heart (the atrium).  The study is done for patients who have not tolerated at least one anti-arrhythmic drug.  This study is of a new  catheter with a wire mesh that delivers radiofrequency energy (called ablation), and will be evaluated to see if it is as safe as and more effective than anti-arrhythmic medication.  The experimental device (the HD Mesh Ablation System, manufactured by C. R. Bard, Inc.) facilitates an ablation technique called “pulmonary vein isolation” (PVI).  This procedure is currently being performed with other ablation catheters.

For more information about this study, please contact Rebecca Baker @417-820-6184
 

Study ID: TRA 2P
Indication: Secondary prevention for patients that have experienced a heart attack, stoke or peripheral artery disease
Physician conducting the study: David Cochran, M.D.
Study Status: Enrolling new patients

The purpose of the study is to evaluate a new blood thinner, SCH 530348 that works along with standard of care (plavix and/or aspirin) in preventing further blood clotting events. The study is looking at the drug given with Plavix and/or aspirin vs. just Plavix and/of aspirin in preventing further events.

For more information about this study, please contact Sherri Swafford, RN at (417) 820-9587
 

Study ID: CHAMPION PCI and Champion Platform (TMC-CAN-05-02 and TMC-CAN-03)
Physician conducting the study: David Cochran, M.D.
Study Status: Enrolling new patients

The purpose of this study is to compare the ability of two drugs to prevent blood clots in patients who have had a heart attack.  Using drugs to prevent clots may be useful in the treatment of patients with heart disease who may be at risk of having a heart attack.  In this study, the standard drug (clopidogrel, also known as Plavix®) used to prevent blood clots is being compared to an investigational drug to see if one works better than the other.

For more information about this study, please contact Kristi Miller @ (417) 820-4338
 

Study ID: CHAMPION (TMC-CAN-05-02)
Indication: Saphenous Vein Grafts
Physician conducting the study: David Cochran, M.D.
Study Status: Starting soon

The purpose of this study is to compare the ability of two drugs to prevent blood clots.  Using drugs to prevent clots may be useful in the treatment of patients with heart disease who may be at risk of having a heart attack.  In this study, the standard drug (clopidogrel, also known as Plavix®) used to prevent blood clots is being compared to an investigational drug to see if one works better than the other.

For more information about this study, please contact Rebecca Baker at (417) 820-6184.